drugset
drugset / Trial / NCT05279235

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

NCT05279235 ↗

Phase 3 Terminated 290 enrolled Shanghai Vinnerna Biosciences Co., Ltd. Sponsor GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) for the Treatment of Coronavirus Disease 2019 (COVID-19) in participants with moderate to severe COVID-19.

Timeline

Start
2022-03-14
Primary completion
2022-12-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Favipiravir Small molecule 600 mg —
Subject JT001 Small molecule 300 mg —

Indications

No indication recorded.